Method for the treatment of threatened abortion
(57) Abstract:Usage: in obstetrics. The inventive pregnant administered indomethacin on the background of peace and psychotherapy, the course of treatment is 7 days. Positive effect: allows you to prolong pregnancy in 97,7% of cases. table 1. The invention relates to medicine, namely to obstetrics.The aim of the invention is to increase the number of cases of prolonged pregnancy to term labor.The method is as follows.Pregnant at admission examined common in obstetric practice methods. In the fine detection of threatened abortion produce hospitalization. Appoint peace and psychotherapy. In the absence of contraindications pregnant impose additional indometacin according to the following scheme: initial single dose of 50 mg daily dose of 200 mg Drug administered 3-4 times a day. Treatment is 5-7 days. The drug is used during or after a meal. In the treatment process to provide individual control for each pregnant woman. Special attention is paid to the state of high energy activity and uterine tone. Repeated courses of treatment therapies.P R I m e R 1. Patient D. , 21, was admitted to the hospital with complaints of lower abdominal pain and lower back pain, frequent urination. When obstetric examination revealed increased tone and excitability of the uterus formed when the cervix.Diagnosis: pregnancy 24 weeks. The threat of miscarriage.The patient is assigned to the peace and held 5 sessions of psychotherapy. Further appointed oral indometacin in tablets 50 mg 4 times a day after meals. The course of treatment was 5 days.In the treatment process was carefully monitoring the patient. Complications and side effects from the applied treatment were observed. After two days of starting treatment improved the General condition decreased the uterine tone.After 5 days from the start of treatment no complaints.When obstetric examination revealed normal tone uterine palpation of the uterus is not excitable.After 10 days of admission to the hospital pregnant in satisfactory condition discharged from the hospital under the supervision of your GP.Control examination after 7 days after discharge from the hospital: no complaints. She feels good. Pennotti ended timely delivery. Weight of the newborn 3350,0, was born with estimation on Apgar scale 7-10 points, the height of 51 seeP R I m m e R 2. Patient S. , 24, was admitted to the hospital with complaints of pains in the lower abdomen, frequent urination, spotting from the vagina.When the obstetric survey found: increased tone and excitability of the uterus with a shortened cervix.Diagnosis: pregnancy 16-17 weeks. The threat of miscarriage.The patient is assigned to physical rest, and conducted 6 sessions of psychotherapy. Further appointed oral indometacin in tablets of 50 mg 3 times a day after meals. The course of treatment was 6 days.In the treatment process was carried out careful monitoring of the condition of the patient. Complications and side effects from the applied treatment is not marked.After three days of starting treatment improved overall health, tone the uterus decreased.After 6 days from the start of treatment no complaints. When obstetric examination was determined by the normal tonus of the uterus, disappeared her anxiety.At the end of 12 days after admission to the hospital pregnant in satisfactory condition discharged home under the supervision WOB no, pregnancy proceeds without complications, on examination, the uterus is not excitable.The pregnancy ended in a timely birth weight newborn 3200,0 height 50 cm, score on a scale of Apgar at birth 9-10 points.P R I m e R 3. Patient K. , 22 years old was admitted to the hospital with complaints of cramping abdominal pain, chromazone from the vagina. When obstetric examination revealed increased tone and excitability of the uterus formed when the cervix.Diagnosis: pregnancy 27 weeks. The threat of miscarriage. Further appointed oral indometacin in tablets of 50 mg 3 times a day after meals. The course of treatment was 7 days.In the treatment process was carefully monitoring the patient. Side effects from the applied treatment is not marked.After 3 days of treatment, the uterine tone dropped significantly, the feeling of "discomfort" in the lower abdomen and also pain in the lower abdomen.After 7 days from the start of treatment no complaints. When obstetric examination was determined by normal uterine tone. At the expiration of 14 days from receipt in the hospital pregnant in a satisfactory condition and was discharged home. examination of the uterus in normal tonus, saved the cervix, the physiological course of pregnancy.The pregnancy ended in a timely birth weight newborn 3900,0 growth of 52 cm, score on a scale of Apgar at birth 9-10 points.The proposed method was treated with 44 women admitted to hospital with a threatened miscarriage. The control group consisted of a group of patients with the same pathology and the severity of the disease, which was treated by the method mentioned in the prototype. The results of the treatment are shown in table.Comparative analysis of the results of the treatment are given in the table shows that the proposed method provided the prolongation of the pregnancy to term the timely delivery in 97,7% of cases (43 and 44 patients offered by way of pregnant women were reported timely delivery).When using the same prototype treatment effect below. Timely delivery were noted only in 83,3-87% of women with threatened miscarriage.The proof of the positive effect of using the invention is evident from the data table, namely, the incidence of prolonging the pregnancy to term labor amounted to 97.7 per cent , higher than that of the prototype. (56) Valutcina P. and other Current is ecologom. M. , 1976, S. 361. Method for the treatment of threatened abortion by administering drugs, characterized in that, to increase the number of cases of prolonged pregnancy to term labor, administered indomethacin in a dose of 50 mg 3 to 4 times a day for 5 to 7 days.
SUBSTANCE: it is suggested to apply tris-(2-hydroxyethyl)ammonium salt of 1-benzylindolyl-3-thioacetic acid earlier known as a stabilizer of cell membrane as preparation to treat autoimmune diseases. The property of the above-mentioned salt to inhibit T-dependent activation of B-lymphocytes, under conditions of decreased medullary function and body leukopenia should enable to develop new pharmacological preparation for treating autoimmune diseases, such as, for example, systemic lupus, rheumatoid polyarthritis, transplant's detachment at transplanting either organs or bony marrow.
EFFECT: higher efficiency of application.
4 ex, 3 tbl
FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to new derivatives of indol-3-yl of the formula (I):
wherein each A and B represents independently of one another oxygen atom (O), NH, CONH, NHCO or a direct bond; X means (C1-C2)-alkylene or a direct bond; R1 means hydrogen atom (H); R2 means hydrogen atom (H); R3 means NHR6, -NR6-C(=NR6)-NHR6, -C(=NR6)-NHR6, -NR6-C(=NR9)-NHR6, -C(=NR9)-NHR6 or Het1; each R4 and R5 represents independently of one another hydrogen atom (H); R7 means -(CH2)o-Ar, Het, OR6; R6 means hydrogen atom (H); R7 means (C1-C10)-alkyl, (C3-C10)-cycloalkyl; R8 means Hal, NO2 (nitro-group), CN (cyano-group), Z, -(CH2)o-Ar, COOR1, OR1, CF3, OCF3, NHR1; R9 means CN or NO2; Z means (C1-C6)-alkyl; Ar means aryl that can represent unsubstituted, monosubstituted, or polysubstituted R8; Hal means F, Cl, Br, J; Het means saturated, partially or completely saturated monocyclic or bicyclic heterocyclic radical comprising from 5 to 10 ring members wherein 1 or 2 nitrogen atom (N) and/or 1 or two sulfur atom (S) present, and heterocyclic radical can be monosubstituted with phenyl; Het1 means saturated, partially or completely unsaturated monocyclic or bicyclic heterocyclic radical comprising from 5 to 10 ring members and from 1 to 4 nitrogen atoms (N) that can be unsubstituted or monosubstituted NHX, or oxo-group; n = 0, 1 or 2; m = 0, 1, 2, 3, 4, 5 or 6; o means 0, 1 or 2; and their physiologically acceptable salts and solvates. Compounds of the formula (I) elicit intergin-inhibitory effect that allows their using as components of pharmaceutical composition. Also, invention describes intermediate compounds.
EFFECT: valuable medicinal properties of compounds.
11 cl, 4 sch, 1 tbl, 34 ex
FIELD: medicine, arthrology, pharmacy.
SUBSTANCE: agent comprises glucosamine salt as saccharide, dimethylsulfoxide, ointment base and ibuprofen or nimesulide, or piroxicam, or meloxicam, or diclofenac salt, or indometacin, or ketoprofen as a nonsteroid anti-inflammatory agent. Glucosamine hydrochloride, glucosamine sulfate sodium, potassium or calcium salt is used as glucosamine, and diclofenac potassium or sodium salt is used as diclofenac salt. New ointment shows high perfusion rate of active substances to the articulation zone and enhanced effectiveness. Invention expands assortment of agents used in treatment of articulations.
EFFECT: improved, enhanced and valuable medicinal properties of agent.
2 cl, 14 ex
FIELD: medicine, arthrology, pharmacy.
SUBSTANCE: invention relates to agents of topical applying used in treatment of articulation diseases. Proposed agent comprises mixture of chondroitin sulfate and glucosamine salts as a saccharide, the compound taken among the group nonsteroid anti-inflammatory agents, in particular, ibuprofen or nimesulid, or piroxicam, or meloxicam, or diclofenac salt, or indometacin, or ketoprofen, dimethylsulfoxide and an ointment base taken in the definite ratio of components. Invention provides enhancing effectiveness due to the content a mixture of low-molecular and high-molecular saccharides in it that results to increasing diffusion rate of active component to the articulation zone and also the compound taken among the group of nonsteroid anti-inflammatory agents. The combined using these agents provides the curative synergetic effect.
EFFECT: improved and valuable medicinal properties of agent.
2 cl, 14 ex
FIELD: chemical-pharmaceutical industry, pharmacy.
SUBSTANCE: invention relates to manufacturing solid medicinal formulations of preparations. Invention proposes a medicinal formulation consisting of a core comprising the following components: indometacin, lactose, calcium phosphate, hydroxypropylcellulose, magnesium stearate, sodium croscarmellose and envelope comprising collicute MAE 100P, propylene glycol, pigment titanium dioxide, talc, collidon-30, brown sycovite-70. Also, invention discloses a method for preparing the formulation. Invention provides enhancing stability of envelope to effect of stomach juice, rapid and complete release of active substance, simultaneous simplifying the process of applying the envelope for a single step.
EFFECT: improved and valuable pharmaceutical properties of formulation.
3 cl, 1 tbl
FIELD: medicine, neurooncology.
SUBSTANCE: one should carry out chemotherapy and irradiation till radical dosage. Moreover, 2-3 d before the onset of radiation therapy and during the whole course of irradiation one should indicate the intake of indometacin at daily dosage being 300 mg, and 8-14 d before the end of therapy course or the stage of radiation therapy it is necessary to conduct chemotherapeutic cycle with vincristine at total dosage being 4 mG and lomustine at total dosage 160-240 mg. At performing a split course of irradiation the intake of indometacin should be indicated between the stages. The innovation enables to increase radio sensitivity of malignant tumor, suppress angiogenesis, proliferative activity and increased cytotoxic activity of chemopreparations.
EFFECT: higher efficiency of therapy.
1 cl, 3 ex
SUBSTANCE: method involves intragastrically introducing indometacin to rats at a dose of 4.5-5 mg/kg of mass after holding the animals without food and water during 5 days.
EFFECT: enhanced effectiveness of bleeding and perforating ulcer formation.
FIELD: medicine, pharmacology, pharmacy.
SUBSTANCE: invention relates to composition possessing an anti-inflammatory effect and useful for oral administration in form of emulsion preliminary concentrate. Composition comprises NO-releasing nonsteroid anti-inflammatory drug, surface-active substance, oil or semisolid fat and forms in situ emulsion of type oil-in-water after contact with aqueous medium, such as gastroenteric fluid. Also, invention relates to a medicinal formulation based on thereof, oral emulsion, set based on thereof and a method for treatment of inflammation and pain. Proposed compositions possess the improved availability.
EFFECT: improved and valuable properties of composition.
40 cl, 1 tbl, 20 ex
FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to new amide derivatives of carboxylic acid that are antagonists of NMDA receptors of the formula (I): , wherein one radical among R1, R2, R3 and R4 represents -OH or NH2-group and others are hydrogen atoms; or two adjacent groups R1, R2, R3 and R4 in this case in common with one or more similar or different additional heteroatoms and -CH= and/or -CH2-groups form 5-6-membvered homo- or heterocyclic ring but preferably pyrrole, pyrazole, imidazole, oxazole, oxooxazolidine or 3-oxo-1,4-oxazine ring; two other groups among R1, R2, R3 and R4 radicals represent hydrogen atoms; R5 and R6 in common with nitrogen atom between them form saturated or unsaturated 4-6-membered heterocyclic ring that is substituted with phenoxy-, phenyl-[(C1-C4)-alkoxy]-, phenoxy-[(C1-C4)-alkyl]-, benzoyl-group optionally substituted in aromatic ring with one or more halogen atoms, (C1-C4)-alkyl or (C1-C4)-alkoxy-group; X and Y mean independently oxygen, nitrogen atom or group -CH=, and to their salts formed with acids and bases. Also, invention relates to a method for preparing compounds of the formula (I) and pharmaceutical compositions showing activity as selective antagonists of NR2B receptor based on these compounds. Invention provides preparing new compounds and pharmaceutical compositions based on thereof for aims in treatment of the following diseases: chronic neurodegenerative diseases, chronic painful states, bacterial and viral infections.
EFFECT: improved preparing method, valuable medicinal properties of compounds and compositions.
11 cl, 2 tbl, 27 ex
FIELD: pharmaceutical technology, pharmacy.
SUBSTANCE: method involves addition sugar-alcohol and/or saccharide showing melting point by 5°C lower or above as compared with the first mentioned sugar-alcohol and/or saccharide to sugar-alcohol and/or saccharide followed by combined treatment of prepared powder by pressing and heating. Invention allows preparing medicinal compositions decomposing in mouth cavity rapidly being without water and showing light using owing to the presence of sufficient strength in preparing, transport in usual using. Method involves mixing, pressing and heating components that represent two or more sugar-alcohol and/or saccharide and active component wherein difference between melting points of one among two or more indicated sugar-alcohol and/or saccharide that shows the higher content and any remaining indicated two or more sugar-alcohol and/or saccharide is 5°C or above. Invention provides preparing strength rapidly soluble tablets.
EFFECT: improved preparing method, improved pharmaceutical properties of composition.
30 cl, 12 tbl, 28 ex